哈三聯(002900.SZ)2021年度淨利潤預增1090.12%–1192.42%
格隆匯2月3日丨哈三聯(002900.SZ)公佈，預計2021年度歸屬於上市公司股東的淨利潤3.49億元-3.79億元，同比增長1090.12%–1192.42%；扣除非經常性損益後的淨虧損1.21億元-1.51億元，上年同期為虧損2115.63萬元。
業績變動原因：(1)公司2021年歸屬於上市公司股東的淨利潤與上年同比上升，主要系非經常性損益的影響。公司於2021年2月9日召開第三屆董事會第九次會議、第三屆監事會第七次會議，審議通過了《關於以全資子公司股權對外投資的議案》，並經2021年第二次臨時股東大會審議通過了《關於以全資子公司股權對外投資的議案》，2021年公司以持有的哈爾濱北星藥業有限公司100%股權對哈爾濱敷爾佳科技發展有限公司進行增資。此次交易價格以2020年12月31日為評估基準日，根據評估結果並經雙方確認，北星藥業100%股權價值為5.7億元。
公司對哈爾濱北星藥業有限公司的初始投資成本351萬元，由此產生投資收益約56649萬元，交易對公司2021年合併報表層面影響利潤總額金額約56649萬元，確認相應的所得税費用後，2021年合併報表層面影響淨利潤金額約48151.65萬元。對具體金額以年審會計師審計後予以確認。
(2)公司以北星藥業對外投資後，其承接公司原有的醫療器械及化粧品生產業務剝離出去，不再納入公司合併範圍。同時持續受國家重點監控合理用藥目錄政策以及新冠疫情的影響，公司醫藥板塊受到較大沖擊，部分產品銷量下滑。兩個因素致使營業收入同比下降30%左右。而工資、折舊、攤銷等固定成本相對穩定，銷售、管理、研發等期間費用同比下降僅10%左右，營業收入不能完全覆蓋營業成本和期間費用，致使公司扣除非經常性損益後的淨利潤為負；
(3)公司依據謹慎性原則，期末對各項資產計提資產減值，本年度資產減值損失預計為1344.51萬元，其中年度累計對存貨計提存貨跌價準備301.44萬元，對投資的黑龍江威凱洱生物技術有限公司計提長期股權投資減值準備1043.07萬元，該項屬於經常性損益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
